Cell Death Discovery (2022) 8(1):427
545 In the ageing brain, AQP4 migrates away from endfeet, which reduces operational capacity of the glymphatic system by ~40%
[7] Because it engages GIP and GLP-1 within one molecule, it is mechanistically distinct from CagriSema, which recruits amylin rather than GIP
Compound synthesis and formulation The different GLP1-based multi-agonists employed in the study, including GLP1/E, GLP1/GIP dual agonist, and GLP1/GIP/glucagon triagonist, as well as the GLP1 mono-agonist, were synthesized, purified and characterized as extensively reported elsewhere 33,34,35,74
Injection site reactions: Mild redness, swelling, or discomfort at injection sites may occur
If not, is this something that could be considered for next year's benefits review